Gastrointestinal endoscopy · 2026
Long-term outcome after endoscopic resection for esophageal squamous cell carcinoma invading muscularis mucosa without lymphovascular invasion: a multicenter retrospective study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kadota Tomohiro, Kawachi Hiroshi, Fujii Satoshi, Yoshio Toshiyuki, Abe Seiichiro, Nagami Yasuaki, Mizuno Ken-Ichi, Kikuchi Daisuke, Yamamoto Yoichi, Ishihara Ryu, Oyama Tsuneo, Nakanishi Hiroyoshi, Katada Chikatoshi, Yamamoto Yoshinobu, Satomi Takuya, Hatta Waku, Kitagawa Yoshiyasu, Hirasawa Kingo, Urabe Yuji, Nakamura Jun, Sugawara Noriaki, Tanaka Tsutomu, Muto Manabu, Tanaka Masaki, Ikeno Takashi, Wakabayashi Masashi, Nakano Kaoru, Inaba Atsushi, Yano Tomonori
Аннотация
BACKGROUND AND AIMS: The need for additional treatment of patients with pathological (p)T1a-muscularis mucosa (MM) (pT1a-MM) esophageal squamous cell carcinoma (ESCC) without lymphovascular invasion (LVI) after endoscopic resection (ER) remains unclear because of the lack of large-scale studies with long-term follow-up. Thus, observations were generally selected as the community standard. We aimed to clarify the long-term outcomes for this patient group.
METHODS: Patients with pT1a-MM ESCC without LVI after ER were retrospectively recruited from 47 institutions between 2008 and 2015. The cumulative recurrence rate (CRR), overall survival (OS), and recurrence-free survival (RFS) were investigated.
RESULTS: Of the 540 patients included, 485 underwent observation, 45 received chemoradiotherapy (CRT), and 10 underwent surgery. The 5-year CRR, OS, and RFS rates for the observation, CRT, and surgery groups were 4.9%, 92.7%, and 89.6%; 2.2%, 93.3%, and 91.1%; and 10.0%, 100%, and 90.0%, respectively.
CONCLUSIONS: Although CRR was not negligible, the current strategy of observation may be a reasonable option given the low recurrence risk.
METHODS: Patients with pT1a-MM ESCC without LVI after ER were retrospectively recruited from 47 institutions between 2008 and 2015. The cumulative recurrence rate (CRR), overall survival (OS), and recurrence-free survival (RFS) were investigated.
RESULTS: Of the 540 patients included, 485 underwent observation, 45 received chemoradiotherapy (CRT), and 10 underwent surgery. The 5-year CRR, OS, and RFS rates for the observation, CRT, and surgery groups were 4.9%, 92.7%, and 89.6%; 2.2%, 93.3%, and 91.1%; and 10.0%, 100%, and 90.0%, respectively.
CONCLUSIONS: Although CRR was not negligible, the current strategy of observation may be a reasonable option given the low recurrence risk.
Предметные рубрики MeSH
HumansEsophageal NeoplasmsRetrospective StudiesFemaleMaleNeoplasm Recurrence, LocalMiddle AgedAgedCarcinoma, Squamous CellNeoplasm InvasivenessDisease-Free SurvivalEsophagectomySurvival RateEsophagoscopyEsophageal Squamous Cell CarcinomaNeoplasm StagingEsophageal MucosaChemoradiotherapyTreatment OutcomeLymphatic MetastasisEndoscopic Mucosal ResectionAdult